SASKATCHEWAN – More cystic fibrosis (CF) patients in Saskatchewan now have access to Trikafta, a groundbreaking medication that improves lung function and quality of life.
As of November 15, the province has expanded coverage to include patients with 152 rare genetic mutations responsive to the drug. This change will extend eligibility to the majority of CF patients in Saskatchewan.
“We are pleased to expand coverage for this treatment for more Saskatchewan people with cystic fibrosis,” said Health Minister Jeremy Cockrill. “We know that Trikafta improves the quality of life for patients, so expanding coverage to include these rare genetic mutations means more CF patients and their families will benefit for years to come.”
A National Recommendation
The expansion follows a November 4 recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH), which advised jurisdictions to broaden Trikafta coverage for CF patients with the additional 152 genetic mutations.
Trikafta was first made available in Saskatchewan in 2021 for patients with the most common CF gene mutation, and coverage was extended to children aged two to five earlier this year. About 95 Saskatchewan residents are already benefiting from the drug, and an estimated 25 more will become eligible under the expanded criteria.
A Lifeline for CF Patients
Cystic fibrosis is a progressive, genetic condition that primarily affects the lungs and digestive system. According to the Canadian Cystic Fibrosis Registry, more than 130 people in Saskatchewan and over 4,400 across Canada live with CF.
Patients with CF, or parents and guardians of children with CF, who believe they may benefit from Trikafta are encouraged to speak with their physician to determine eligibility.
A Step Forward for CF Care
The expanded access to Trikafta is a significant step forward in improving health outcomes for CF patients. “This treatment has already made a profound difference for many people, and with this expansion, even more Saskatchewan families will have hope for a better future,” Cockrill said.
This initiative underscores the province’s commitment to ensuring patients living with rare diseases like CF have access to life-changing treatments.